How pain and physical medicine groups vet suppliers
Multi-provider pain and physical medicine groups in this region generally centralize vendor review with a practice manager or compliance lead rather than leaving it to individual physicians. That person typically requests a sample certificate of analysis, confirms the lot-level traceability process, and checks that order minimums and account terms fit the group's purchasing workflow before the first order is placed.
Because this clinic type often carries multiple product families in inventory at once, groups commonly ask us to walk through the distinction between the Wharton's jelly line (Bio PRP Jelly, Bio Flex, Bio Flow, Bio DPM) and the exosome line (Bio Xsomes, Bio EX, Bio AER) during onboarding, since the two families carry different regulatory framing.
Santa Rosa
NPPES registry listings, primary taxonomy, retrieved 2026-10-27
63- Pain Medicine
- 26
- Physical Medicine & Rehabilitation
- 37
NPI-verified accounts
Every account requires a valid individual or group NPI number, matching the structure NPPES uses to register providers. This applies equally to solo pain physicians and larger physical medicine groups with multiple locations.
Cold-chain receiving and documentation
Cryopreserved orders ship overnight on dry ice in validated containers from dispatch, with lot-level tracking from the supplier side through to patient-record traceability on the clinic side. Lyophilized formats, including Bio DPM, Bio EX, and Bio AER, are shelf-stable and do not require dry-ice handling, which some multi-site groups prefer for locations without a dedicated receiving process. We recommend practices confirm the California medical board license status of each prescribing physician and route any use-case questions to independent counsel; these products are not FDA approved or licensed for any disease or condition.
Account support
Once an account is verified, our team offers peer-to-peer calls between physicians focused on documentation review, and makes certificates of analysis, donor eligibility summaries, and lot release records available on request for every shipment.
FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
Can a physical medicine and rehabilitation practice order the same products as a pain management clinic?+
Yes. Account eligibility is based on licensure and NPI verification, not on which taxonomy a practice is registered under.
Are exosome products regulated the same way as Wharton's jelly products?+
No. FDA has stated there are no FDA-approved exosome products and treats them generally as biologic drugs under section 351. Wharton's jelly products are offered under the supplier's HCT/P framework; whether a given use qualifies under 21 CFR 1271.10 is a determination for your practice and counsel.
How do multi-location groups handle traceability across sites?+
Each lot carries a unique identifier from the supplier. Clinics are responsible for logging that identifier at the patient record level at whichever location receives the shipment.